Compare PDLB & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | SRZN |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 323.9M |
| IPO Year | 2021 | N/A |
| Metric | PDLB | SRZN |
|---|---|---|
| Price | $17.53 | $29.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 49.7K | ★ 76.4K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $75.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.88 | $7.11 |
| 52 Week High | $18.01 | $30.49 |
| Indicator | PDLB | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 68.59 | 62.60 |
| Support Level | $15.84 | $23.56 |
| Resistance Level | $18.01 | N/A |
| Average True Range (ATR) | 0.36 | 2.05 |
| MACD | 0.10 | 0.20 |
| Stochastic Oscillator | 81.94 | 81.73 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).